# PhaseV

> PhaseV provides causal AI, trial simulation and workflow software for biopharma sponsors and CROs. Its tools identify potential responder subgroups, compare study designs, plan recruitment, guide portfolio choices and automate clinical documentation and statistical programming.

- **Founded:** 2023
- **Headquarters:** Cambridge, United States
- **Founders:** Raviv Pryluk (CEO and Co-Founder), Elad Berkman (CTO and Co-Founder), Dan Goldstaub (Scientific Co-Founder)
- **Products:** Trial Optimizer, Response Optimizer, Portfolio Optimizer, ClinOps Optimizer, Enrollment Lab
- **Notable:** US$65 million in announced funding through May 2025., Reported more than 100 supported clinical programs and more than 50 global sponsors in September 2026., Oramed responder analysis contributed to plans for a differentiated oral-insulin study protocol following a failed U.S. trial.

## Products & services

- **Trial Optimizer** — Simulates and compares fixed, Bayesian and adaptive Phase 1-3 trial designs, with optimization of sample size and interim decisions under statistical constraints.
- **Response Optimizer** — Analyzes treatment-effect heterogeneity to identify candidate responder subgroups and biomarkers; includes sensitivity and robustness checks.
- **Portfolio Optimizer** — Uses causal disease graphs to explore biomarker-outcome links, treatment combinations and indication choices.
- **ClinOps Optimizer** — Supports patient-informed site selection and monitoring of enrollment, progression and dropout. ClinOps platform launch announced July 1, 2025.
- **Enrollment Lab** — Models eligibility and competition using real-world EHR data before protocol lock; announced February 2, 2026.
- **AI Conductor** — Connects clinical authoring, standardized datasets, statistical programming and reporting with collaboration and audit history; launched March 17, 2026.
- **Technology-enabled services** — Project-based ML, statistics and clinical expertise, with scope, cost and timelines agreed with the sponsor.

## Achievements

- US$65 million in announced funding through May 2025.
- Reported more than 100 supported clinical programs and more than 50 global sponsors in September 2026.
- Oramed responder analysis contributed to plans for a differentiated oral-insulin study protocol following a failed U.S. trial.
- Published research includes causal responder detection and treatment-effect estimation methods.
- Company reports up to 50% cost reductions, up to 40% shorter trial durations and over 30% higher probability of success in collaborations; these are not universal or independently guaranteed outcomes.

## Latest updates

- **2026-09** — Klaus Beck and Avi Kulkarni appointed to the Scientific Advisory Board to guide expansion of AI Conductor; announcement reports 100+ programs and 50+ sponsors.
- **2026-08** — Released a commissioned industry survey describing clinical reporting and data-workflow delays.
- **2026-03** — Launched AI Conductor for protocol-to-submission workflows.
- **2026-02** — Launched Enrollment Lab at SCOPE Summit to model enrollment before protocol lock.

## Links

- Website: https://www.phasevtrials.com/
- LinkedIn: https://www.linkedin.com/company/phasevtrials/

---

Profile page: https://yespress.io/phasev
Published by YesPress — https://yespress.io
Last updated: 2026-10-06